Investors in EPIX have chance to take lead in ESSA Pharma Inc. securities fraud case

Investors in EPIX now have the chance to take the lead position in a securities fraud lawsuit against ESSA Pharma Inc., according to the Rosen Law Firm. This development arises from allegations that ESSA Pharma Inc. made false and misleading statements to investors. These deceptive practices allegedly led to inflated stock prices for EPIX.

The Rosen Law Firm, a global investor rights law firm, specializes in securities class action lawsuits. They are actively investigating the potential securities claims on behalf of EPIX investors. The firm encourages anyone who purchased EPIX shares between February 5, 2019, and September 17, 2021, to contact them to learn more about the lawsuit.

The alleged securities fraud by ESSA Pharma Inc. centers around the company’s positive statements regarding the effectiveness of its prostate cancer treatment drug, EPI-7386. The lawsuit claims that ESSA falsely represented that the drug showed promising trial results and had a high likelihood of receiving FDA approval. However, it is alleged that the company knew or should have known that the drug would not receive approval based on the available data.

As a result of these false representations, the lawsuit alleges that EPIX stock prices were artificially inflated. When the truth about EPI-7386’s efficacy and likelihood of approval was revealed, the stock prices plummeted, causing substantial financial losses for investors.

Investors who suffered financial losses due to EPIX’s alleged securities fraud now have the opportunity to take legal action against ESSA Pharma Inc. The Rosen Law Firm is actively seeking to recover losses on behalf of affected investors. They are dedicated to holding companies accountable for their deceptive practices and protecting investors’ rights.

Investors who purchased EPIX shares between February 5, 2019, and September 17, 2021, should contact the Rosen Law Firm to learn more about the securities fraud lawsuit. By participating in the legal action, investors can potentially recover their losses and hold ESSA Pharma Inc. accountable for its alleged misconduct.

In conclusion, investors in EPIX have the opportunity to take the lead in a securities fraud lawsuit against ESSA Pharma Inc. The lawsuit alleges that ESSA made false and misleading statements about the efficacy and likelihood of approval of its prostate cancer treatment drug, EPI-7386. By participating in the lawsuit, investors can seek to recover losses caused by the alleged securities fraud and hold ESSA accountable for its deceptive practices. Contact the Rosen Law Firm for more information on joining the lawsuit and protecting your rights as an investor.